Market Closed -
Hong Kong S.E.
04:08:13 2024-07-03 EDT
|
5-day change
|
1st Jan Change
|
3.4
HKD
|
0.00%
|
|
+4.29%
|
-48.25%
|
06-28 |
RecoRNA(Guangzhou) Biotechnology Co., Ltd announced that it has received funding from Beijing Zhongguancun Capital Fund Management Co., Ltd., Tian Tu Capital Co., Ltd., Yael Capital, Hangzhou Xiaochi Private Equity Fund Management Co., Ltd., BeiGene Bio Island Innovation Center and other investors
|
CI
| 06-17 |
Leman Biotech Co., Ltd. announced that it has received CNY 50 million in funding from FUHO Capital Management Co., Ltd., XtalPi Inc., Henan Yunfan Electronic Technology Co., Ltd., Tian Tu Capital Co., Ltd. and other investors
|
CI
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
4,138
|
2,193
|
-
|
-
|
Enterprise Value (EV)
1 |
4,138
|
2,193
|
2,193
|
2,193
|
P/E ratio
|
-3.83
x
|
4.51
x
|
3.84
x
|
3.91
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-5.38
x
|
2.94
x
|
2.33
x
|
2.27
x
|
EV / Revenue
|
-5.38
x
|
2.94
x
|
2.33
x
|
2.27
x
|
EV / EBITDA
|
-4.77
x
|
3.55
x
|
2.7
x
|
2.63
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
Price to Book
|
0.46
x
|
0.28
x
|
0.26
x
|
0.25
x
|
Nbr of stocks (in thousands)
|
693,031
|
693,031
|
-
|
-
|
Reference price
2 |
5.972
|
3.164
|
3.164
|
3.164
|
Announcement Date
|
24-03-28
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-769.1
|
746
|
943
|
968
|
EBITDA
1 |
-
|
-867.6
|
618
|
813
|
835
|
EBIT
1 |
-
|
-881
|
604
|
799
|
821
|
Operating Margin
|
-
|
114.55%
|
80.97%
|
84.73%
|
84.81%
|
Earnings before Tax (EBT)
1 |
759.9
|
-959.9
|
635
|
765
|
752
|
Net income
1 |
616.4
|
-873
|
486
|
571
|
561
|
Net margin
|
-
|
113.51%
|
65.15%
|
60.55%
|
57.95%
|
EPS
2 |
-
|
-1.560
|
0.7020
|
0.8230
|
0.8100
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
23-03-31
|
24-03-28
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
6.4%
|
7%
|
6.5%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
3%
|
3.7%
|
3.5%
|
Assets
1 |
-
|
-
|
16,200
|
15,432
|
16,029
|
Book Value Per Share
2 |
-
|
13.00
|
11.20
|
12.10
|
12.90
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
2.33
|
7
|
7
|
6
|
Capex / Sales
|
-
|
-0.3%
|
0.94%
|
0.74%
|
0.62%
|
Announcement Date
|
23-03-31
|
24-03-28
|
-
|
-
|
-
|
Last Close Price
3.164
CNY Average target price
8.694
CNY Spread / Average Target +174.79% Consensus |